AUMMUNE
Updated 33 days ago
Tel Aviv Medical Center (TAMC), Sammy Ofer Building, Floor 10 Weizmann St 6, Tel Aviv-Yafo, ISRAEL
Aummune is a clinical stage company developing a first-of-its-kind approach for individualized treatment of solid tumors. Our proprietary platform utilizes a unique efficacy-driven selection process to match and produce a patient-specific tri-functional oligonucleotide drug that safely and synergistically induces cancer cell death and activates both innate and adaptive immune responses...
Aummune's lead program, AM003, has already initiated its Phase 1 clinical trial following successful demonstrations of efficacy and safety in multiple animal models. The company is now actively recruiting patients for this First-in-Human study, which targets those with locally advanced and metastatic solid tumors
Also known as: Aummune Therapeutics, Aummune Therapeutics Ltd.